The investment will be used to further extend Ultivue’s leadership position primarily through the expansion of its portfolio of UltiMapper™ kits with an increasing level of product customization. Ultivue will also significantly accelerate its international market presence with increased investments in sales, field application scientists and marketing across all regions with an immediate focus on Asia.
“We are delighted to receive the backing of Northpond Ventures in addition to our existing investors as we advance the field of multiplex biomarker detection and analysis for tissue phenotyping,” said Michael Natan, CEO of Ultivue. “This latest round of financing sets the stage for substantial growth and allows us to continue developing the innovation to meet the evolving needs of our customers in translational and clinical research.”
“The fast market adoption of Ultivue’s reagents and services is making an impact in the field of immuno-oncology research and we are excited to work together ...